See the DrugPatentWatch profile for teflaro

Based on the information available, there is currently no definitive timeline for the generic release of Teflaro (ceftaroline fosamil). Ceftaroline fosamil is an antibiotic used to treat acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia [1]. The drug is marketed by Forest Laboratories, a subsidiary of Allergan plc [1].

According to DrugPatentWatch.com, Teflaro's patent expired in the United States on June 28, 2020 [2]. However, this does not necessarily mean that a generic version of Teflaro will be immediately available in the market. The process of bringing a generic drug to market can be lengthy and complex, involving various stages such as bioequivalence studies, manufacturing scale-up, and regulatory approval [3].

Therefore, while the expiration of Teflaro's patent is a necessary step for generic entry, it is not a sufficient condition for the immediate availability of a generic version of the drug. It is important to note that the actual timeline for the generic release of Teflaro will depend on various factors, including the interest and resources of potential generic manufacturers, regulatory approval timelines, and other market dynamics [3].

In summary, while Teflaro's patent has expired, there is currently no definitive timeline for the generic release of the drug. The process of bringing a generic drug to market can be lengthy and complex, involving various stages such as bioequivalence studies, manufacturing scale-up, and regulatory approval.

Sources:

1. Teflaro (ceftaroline fosamil) for injection, prescribing information. Forest Pharmaceuticals, Inc., a subsidiary of Allergan plc. April 2019. Available at: <https://www.allergan.com/assets/pdf/teflaro_pi.pdf>.
2. DrugPatentWatch.com. Ceftaroline Fosamil. Available at: <https://www.drugpatentwatch.com/drugs/ceftaroline-fosamil>.
3. U.S. Food and Drug Administration. Generic Drugs: Questions and Answers. Available at: <https://www.fda.gov/drugs/development-approval-process-drugs/generic-drugs-questions-and-answers>.